CLS (CHARTER LIFE SCIENCES) is an early stage life sciences venture capital investor.

CLS makes initial portfolio company investments in life sciences companies that are seeking capital to obtain initial proof-of-efficacy of their products (see Investment Criteria), and we continue to support our successful portfolio companies with follow on investments until they are acquired or go public.

Our team is led by four Managing Partners who have worked together to create and build life sciences companies for over twenty years. Our team brings extensive scientific, clinical, regulatory, operational and finance experience to each of our portfolio companies.

We play an active role in helping entrepreneurs build successful companies. Our time, energy and passion is devoted to building early stage life sciences opportunities. As a result, your company will be compared only against other early stage opportunities. So, at CLS, your early stage biotech medical device or health care information technology company will not be compared against a PIPE investment in an undervalued Phase III company, as an example. Early stage is what we do, and all we do.


We understand that early stage companies do not have all the answers and do not have all the data. We understand that many basic questions need investment capital to answer, and we understand that development plans and milestones are subject to lots of uncertainty and change. We understand what it takes to build a management team from scratch, and we invest in companies with little or no existing management. In short, we understand what it is to be an early stage entrepreneur, because each of us has been one.

Please look carefully at our investment criteria and our team, and if we are the type of partner that you would like to work with, please contact us.

In the News

-  At 12 Months, Gastric Vest System™ Patients Demonstrated Excess Weight Loss (EWL) of 85% and Waist Circumference Reduction of 38 Centimeters - -  Company to Host Conference Call Today at 10:00 AM Eastern Time  EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices treating obesity, metabolic diseases and other gastrointestinal disorders, announced today that it has acquired the Gastric Vest System™ (the "Gastric Vest" or "Vest"), through its acquisition of BarioSurg, Inc. The Gastric Vest is an investigational, minimally-invasive, laparoscopically implanted medical device being studied for weight loss in morbidly obese patients. The device, which wraps around the stomach and [more]
EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced it has been named a 2017 Bronze Edison Award Winner by the internationally renowned Edison Awards™ in the Health and Wellness category for its vBloc® Neurometabolic Therapy for the treatment of obesity. The Edison Awards, inspired by Thomas Edison's persistence and inventiveness, recognize innovation, creativity and ingenuity in the global economy. Award winners were announced April 20, 2017 at the Edison Awards Annual Gala in New York City. "It's exciting to see companies like EnteroMedics continuing Thomas Edison's [more]